

Jason D Goldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4227621/publications.pdf>

Version: 2024-02-01

38
papers

6,516
citations

394421

19
h-index

395702

33
g-index

51
all docs

51
docs citations

51
times ranked

14341
citing authors

#	ARTICLE	IF	CITATIONS
1	Covid-19 in Critically Ill Patients in the Seattle Region – Case Series. <i>New England Journal of Medicine</i> , 2020, 382, 2012-2022.	27.0	2,120
2	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1827-1837.	27.0	1,152
3	Multiple early factors anticipate post-acute COVID-19 sequelae. <i>Cell</i> , 2022, 185, 881-895.e20.	28.9	605
4	Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1407-1418.	10.7	501
5	Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. <i>Cell</i> , 2020, 183, 1479-1495.e20.	28.9	449
6	Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e4090-e4099.	5.8	332
7	Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13507.	1.6	131
8	Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 327-336.	10.7	131
9	Use of convalescent plasma in hospitalized patients with COVID-19: case series. <i>Blood</i> , 2020, 136, 759-762.	1.4	124
10	Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19. <i>Nature Biotechnology</i> , 2022, 40, 110-120.	17.5	81
11	COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. , 2021, 9, e002630.		76
12	Simple Adherence Assessments to Predict Virologic Failure among HIV-Infected Adults with Discordant Immunologic and Clinical Responses to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1031-1035.	1.1	74
13	Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. <i>American Journal of Transplantation</i> , 2022, 22, 279-288.	4.7	63
14	Characteristics and Factors Associated With Coronavirus Disease 2019 Infection, Hospitalization, and Mortality Across Race and Ethnicity. <i>Clinical Infectious Diseases</i> , 2021, 73, 2193-2204.	5.8	41
15	A Population-Level Evaluation of the Effect of Antiretroviral Therapy on Cancer Incidence in Kyadondo County, Uganda, 1999–2008. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 481-486.	2.1	40
16	COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study. <i>American Journal of Transplantation</i> , 2021, 21, 2774-2784.	4.7	37
17	HIV, hepatitis B, and hepatitis C in Zambia. <i>Journal of Global Infectious Diseases</i> , 2011, 3, 269.	0.5	34
18	Remdesivir and Mortality in Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2022, 74, 1812-1820.	5.8	25

#	ARTICLE	IF	CITATIONS
19	Cryptococcosis in the immunocompetent patient. <i>Respiratory Care</i> , 2010, 55, 1499-503.	1.6	21
20	Racial Disproportionality in Covid Clinical Trials. <i>New England Journal of Medicine</i> , 2020, 383, 2486-2490.	27.0	20
21	Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation. <i>Hepatology Communications</i> , 2018, 2, 1446-1450.	4.3	14
22	Surge effects and survival to hospital discharge in critical care patients with COVID-19 during the early pandemic: a cohort study. <i>Critical Care</i> , 2021, 25, 70.	5.8	14
23	A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics. <i>PLoS ONE</i> , 2010, 5, e9680.	2.5	12
24	Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons. <i>Infectious Agents and Cancer</i> , 2016, 11, 7.	2.6	12
25	Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0259902.	2.5	10
26	Intra-host changes in Kaposi sarcoma-associated herpesvirus genomes in Ugandan adults with Kaposi sarcoma. <i>PLoS Pathogens</i> , 2021, 17, e1008594.	4.7	9
27	COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 176-188.	3.8	7
28	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. <i>Clinical Infectious Diseases</i> , 2024, 78, 711-718.	5.8	6
29	Perspectives on COVID-19 and cancer immunotherapy: a review series. , 2021, 9, e002489.		4
30	Infusion-Compatible Antibiotic Formulations for Rapid Administration to Improve Outcomes in Cancer Outpatients With Severe Sepsis and Septic Shock: The Sepsis STAT Pack. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 457-464.	4.9	3
31	Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic. <i>Clinical Infectious Diseases</i> , 2021, 72, e844-e847.	5.8	3
32	Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106174.	2.5	3
33	Healthcare resource use among solid organ transplant recipients hospitalized with COVID-19. <i>Clinical Transplantation</i> , 2021, 35, e14174.	1.6	3
34	Algid malaria treated with early goal-directed therapy. <i>American Journal of Emergency Medicine</i> , 2013, 31, 263.e5-263.e10.	1.6	2
35	HIV Transmission During Condomless Sex With a Seropositive Partner With Suppressed Infection. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2044.	7.4	1
36	Reszinate™ A Phase 1/2 Randomized Clinical Trial of Zinc and Resveratrol Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling. <i>Frontiers in Drug Discovery</i> , 0, 2, .	2.8	1

#	ARTICLE	IF	CITATIONS
37	LB3. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomized, Placebo-Controlled Trial. <i>Open Forum Infectious Diseases</i> , 2021, 8, S808-S809.	0.9	0
38	126. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection and Vaccination. <i>Open Forum Infectious Diseases</i> , 2021, 8, S77-S77.	0.9	0